Cardiovascular Risk Factors in Non-Diabetic Hemodialysis Patients: A Comparative Study

REFERENCES

• Locatelli F, et al. Cardiovascular disease in chronic renal failure: The challenge continues. Registro Lombardo Dialisi e Trapianto. Nephrol Dial Transplant. 2000; 15(Suppl)69–80
   Google Scholar
• Whitaker JN. Effects of pregnancy and delivery on disease activity in multiple sclerosis. N Engl J Med. 1998; 339(5)339–340
   Google Scholar
• Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000; 356(9224)147–152
   PubMed Web of Science ®Google Scholar
• U.S. Renal Data System (USRDS). Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md 2007
   Google Scholar
• Bianchi G. Hypertension in chronic renal failure and end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Nephrol Dial Transplant 2000; 15(Suppl. 5)105–110
   Google Scholar
• Webb AT, et al. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant. 1995; 10(3)354–357
   Google Scholar
• Sarnak MJ, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002; 57(5)327–335
   PubMed Web of Science ®Google Scholar
• Muntner P, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004; 140(1)9–17
   Google Scholar
• Longenecker JC, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol. 2002; 13(7)1918–1927
   PubMed Web of Science ®Google Scholar
• Bolton CH, et al. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001; 16(6)1189–1197
   Google Scholar
• Bostom AG, et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis. 1996; 125(1)91–101
   Google Scholar
• Pawlak K, et al. Oxidative stress—a link between endothelial injury, coagulation activation, and atherosclerosis in hemodialysis patients. Am J Nephrol. 2004; 24(1)154–161
   Google Scholar
• Liu Y, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004; 291(4)451–459
   PubMed Web of Science ®Google Scholar
• Boaz M, et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis. 1999; 34(3)438–444
   Google Scholar
• Shoji T, Nishizawa Y. Chronic kidney disease as a metabolic syndrome with malnutrition—need for strict control of risk factors. Intern Med. 2005; 44(3)179–187
   Google Scholar
• Orem C, et al. Plasma fibronectin level and its association with coronary artery disease and carotid intima-media thickness. Coron Artery Dis. 2003; 14(3)219–224
   Google Scholar
• Goldwasser P, et al. Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis. 1994; 24(5)785–794
   Google Scholar
• Wirta O, et al. Renal and cardiovascular predictors of nine-year total and sudden cardiac mortality in non-insulin-dependent diabetic subjects. Nephrol Dial Transplant. 1997; 12(12)2612–2617
   Google Scholar
• Horl MP, Horl WH. Hemodialysis-associated hypertension: Pathophysiology and therapy. Am J Kidney Dis. 2002; 39(2)227–244
   Google Scholar
• Jungers P, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant. 1997; 12(12)2597–2602
   Google Scholar
• Zager PG, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998; 54(2)561–569
   Google Scholar
• Stidley CA, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol. 2006; 17(2)513–520
   Google Scholar
• Mominadam S, et al. Interdialytic blood pressure obtained by ambulatory blood pressure measurement and left ventricular structure in hypertensive hemodialysis patients. Hemodial Int. 2008; 12(3)322–327
   Google Scholar
• Tomita J, et al. Role of systolic blood pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis. 1995; 25(3)405–412
   Google Scholar
• Foley RN, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end–stage renal disease. Kidney Int. 1996; 49(5)1379–1385
   PubMedGoogle Scholar
• Magnusson MK, Mosher DF. Fibronectin: Structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol. 1998; 18(9)1363–1370
   PubMed Web of Science ®Google Scholar
• Yamada KM. Fibronectin peptides in cell migration and wound repair. J Clin Invest. 2000; 105(11)1507–1509
   Google Scholar
• Mosher DF. Plasma fibronectin concentration: A risk factor for arterial thrombosis?. Arterioscler Thromb Vasc Biol. 2006; 26(6)1193–1195
   Google Scholar
• Tan MH, et al. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood. 2004; 104(1)11–18
   Google Scholar
• Yee KO, Schwartz SM. Why atherosclerotic vessels narrow: The fibrin hypothesis. Thromb Hemost. 1999; 82(2)762–771
   Google Scholar
• Song KS, et al. Plasma fibronectin levels in ischemic heart disease. Atherosclerosis. 2001; 154(2)449–453
   Google Scholar
• Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000; 102(10)1082–1085
   PubMed Web of Science ®Google Scholar
• Ridker PM, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004; 109(25 Suppl. 1)IV6–IV19
   PubMed Web of Science ®Google Scholar
• Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003; 349(22)2108–2115
   PubMed Web of Science ®Google Scholar
• Hancock MA, et al. Inhibition of plasminogen activation by lipoprotein(a): Critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003; 278(26)23260–23269
   PubMed Web of Science ®Google Scholar
• Buechler C, et al. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood. 2001; 97(4)981–986
   Google Scholar
• Berglund L, Ramakrishnan R. Lipoprotein (a): An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004; 24(12)2219–2226
   PubMed Web of Science ®Google Scholar
• Quaschning T, et al. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis. 2001; 38(4 Suppl. 1)S14–S9
   PubMed Web of Science ®Google Scholar
• Tzanatos HA, et al. Cytokine release and serum lipoprotein (a) alterations during hemodialysis. Artif Organs. 2000; 24(5)329–333
   Google Scholar